Celcuity LLC (CELC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celcuity LLC (CELC) has a cash flow conversion efficiency ratio of -0.383x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.82 Million) by net assets ($116.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Celcuity LLC worth for the company's overall valuation and market capitalisation.
Celcuity LLC - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Celcuity LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Celcuity LLC for real-time trading data and today's change.
Celcuity LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celcuity LLC ranked by their cash flow conversion efficiency. Review financial flexibility index of Celcuity LLC to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ming Yang Smart Energy Group Ltd
SHG:601615
|
-0.050x |
|
Huaneng Power International Inc
F:HUP1
|
0.034x |
|
ABCELLERA BIOLOGICS
F:8QQ
|
0.029x |
|
Alleima AB (publ)
ST:ALLEI
|
0.044x |
|
National Health Investors Inc
NYSE:NHI
|
0.035x |
|
Shanghai Bright Power Semiconductor
SHG:688368
|
0.016x |
|
Aditya Birla Sun Life AMC Limited
NSE:ABSLAMC
|
0.095x |
|
Assured Guaranty Ltd
NYSE:AGO
|
0.034x |
Annual Cash Flow Conversion Efficiency for Celcuity LLC (2015–2024)
The table below shows the annual cash flow conversion efficiency of Celcuity LLC from 2015 to 2024. Also see Celcuity LLC assets under control for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $115.62 Million | $-83.47 Million | -0.722x | -87.51% |
| 2023-12-31 | $139.77 Million | $-53.81 Million | -0.385x | -43.03% |
| 2022-12-31 | $133.77 Million | $-36.01 Million | -0.269x | +8.94% |
| 2021-12-31 | $68.71 Million | $-20.31 Million | -0.296x | +51.59% |
| 2020-12-31 | $11.70 Million | $-7.15 Million | -0.611x | -96.43% |
| 2019-12-31 | $19.30 Million | $-6.00 Million | -0.311x | -29.68% |
| 2018-12-31 | $25.35 Million | $-6.08 Million | -0.240x | -52.07% |
| 2017-12-31 | $31.39 Million | $-4.95 Million | -0.158x | +69.38% |
| 2016-12-31 | $5.61 Million | $-2.89 Million | -0.515x | -30.48% |
| 2015-12-31 | $5.02 Million | $-1.98 Million | -0.394x | -- |
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2… Read more